Mirtastad (Mirtazapine)

Mirtazapine, the active ingredient in Mirtastad, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients, where it helps to alleviate depressive symptoms, improve mood, and restore normal sleep patterns.

GNH USA supplies Mirtastad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑controlled medication for mental health care with full regulatory documentation and export certifications.

Mirtazapine is employed in the management of depressive disorders, acting on noradrenergic and serotonergic pathways to restore neurotransmitter balance.

- Major depressive disorder: reduces depressive symptoms, improves mood, and enhances overall functioning in adults.

Mirtazapine may cause a range of adverse reactions, some of which are frequent and others that are uncommon but serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness or light‑headedness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Serotonin syndrome, especially with other serotonergic agents - Severe hypersensitivity reactions (rash, angioedema, anaphylaxis) - Suicidal thoughts or behavior, particularly early in treatment - Hepatic dysfunction or jaundice - Seizures in predisposed individuals

Before initiating therapy, clinicians should evaluate patient history and monitor for specific safety concerns.

- Monitor weight and metabolic parameters: mirtazapine can increase appetite and cause weight gain. - Assess for suicidal ideation: watch for worsening mood, especially during the first weeks. - Use caution in hepatic impairment: dose adjustment may be required. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms. - Evaluate concomitant CNS depressants: increased sedation may occur. - Store below 25°C: keep in the original pack, protect from moisture.

Mirtazapine can interact with several drug classes, requiring careful assessment of co‑medications.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): heightened serotonin toxicity.

Moderate Interactions (Monitor Closely): - Central nervous system depressants (benzodiazepines, alcohol): additive sedation. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Antihistamines: potential for enhanced drowsiness. - Anticholinergic drugs: may exacerbate dry mouth and constipation. - Blood thinners (warfarin): monitor INR for possible changes.